Bisphenol A (BPA) strongly binds to human estrogenrelated receptor c (ERRc). BPA is an oestrogenic endocrine disruptor that influences various physiological functions at very low doses. BPA functions as an inverse-type antagonist of ERRc to retain its high basal constitutive activity by inhibiting the deactivating inverse agonist activity of 4-hydroxytamoxifen (4-OHT). We recently demonstrated that ERRc receptor residues Glu275 and Arg316 function as the intrinsic binding site of BPA's phenol-hydroxyl group. We also determined the chief importance of phenolhydroxyl$Arg316 hydrogen bonding and the corroborative role of phenol-hydroxyl$Glu275 hydrogen bonding. However, there appeared to be a distinct difference between the receptor binding modes of BPA and 4-OHT. In the present study, using tritium-labelled or non-labelled BPA and 4-OHT, we evaluated in detail the receptor binding capabilities of wild-type ERRc and its mutants with amino acid alterations at positions 275 and 316. Both compounds exhibited a strong binding ability to wild-type ERRc due to the hydrogen bonding to Glu275 and Arg316. However, 4-OHT revealed significantly reduced occupancy for both wild-type and mutant receptors. The data obtained suggest that 4-OHT barely binds to ERRc due to the strong ability of Glu275 and Arg316 to recruit phenol compounds.
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Bisphenol A [BPA; 2,2-bis(4-hydroxyphenyl)propane], has recently been found to bind strongly to estrogen-related receptor g (ERRg) with high constitutive basal activity (1) . ERRg is one of the 48 human nuclear receptors (NRs) (2, 3) , while BPA has long been recognized as an estrogenic chemical able to interact with human estrogen receptor (ER) (46). Various 'low-dose effects' of BPA have recently been reported in vivo for many organ tissues and systems in mice and rats (710). However, since the discovery of ERRg, it became an immediate and important requirement to evaluate whether the previously reported effects of BPA at low doses are mediated through ERRg and its specific target gene(s) (11) .
BPA has the chemical structure of HOC 6 H 4 C(CH 3 ) 2 C 6 H 4 OH with two phenol groups ( Fig. 1) . We have recently reported the crystallization and structural analysis of the BPA/ ERRg-ligand binding domain (LBD) complex (12) . In the complex, a single molecule of BPA stays at the ligand-binding pocket of each ERRg-LBD protein molecule, whose a-helix 12 (H12) is stabilized in an activation conformation. The crystal structure of the complex suggests several essential interactions between the BPA and ERRg-LBD molecules. For instance, BPA's phenol-hydroxyl group is tethered by hydrogen bonds to the Glu275 and Arg316 residues in the ERRg-LBD (Fig. 2) . These hydrogen bonds were also observed in the ERRgLBD complex with 4-a-cumylphenol (13) . Since 4-a-cumylphenol is a compound that lacks one of BPA's phenol-hydroxyl groups, the results clearly indicated that the hydrogen bonds of the phenol-hydroxyl group to the Glu275 and Arg316 residues are crucial for binding of the phenol compounds to ERRg. Indeed, by examining the ERRgLBD analogues through site-directed mutagenesis, we demonstrated these residues as the intrinsic binding site of BPA's phenol-hydroxyl group (14) .
Similar hydrogen bonding was also found in the complex between 4-hydroxytamoxifen (4-OHT, Fig. 1 ) and ERRgLBD (15). 4-OHT deactivates ERRg in, for example, the luciferase reporter gene assay (1, 16, 17) . BPA inhibits such inverse agonist activity of 4-OHT. BPA reverses the deactivation to the originally high basal activation state in a dosedependent manner, and thus acts as an inverse antagonist of ERRg (1) . Although the phenol-hydroxyl group of 4-OHT shares the same site for its binding to ERRg, the difference in receptor binding modes between BPA and 4-OHT remains to be clarified.
In the previous study we elucidated the chief importance of phenol-hydroxyl$Arg316 hydrogen bonding and the corroborative role of phenol-hydroxyl $Glu275 hydrogen bonding (14) . This result strongly suggested that the formation of these double hydrogen bonds is critical for phenol compounds to bind to ERRg. In the present study, to shed light on the structural significance of these double hydrogen bonds, we carried out a detailed comparison between BPA and 4-OHT for binding to ERRgLBD in a site-directed point mutagenesis series. We here report that human NR ERRg binds highly specifically to BPA, but barely binds to the inverse agonist 4-OHT. Plasmid construction and site-directed mutagenesis A cDNA fragment encoding wild-type ERRgLBD (residues 222458) was generated by polymerase chain reaction (PCR) with specific primers using the human kidney cDNA library (Clontech Laboratories; Mountain View, CA, USA) and cloned into the vector pGEX-6p-1 (Amersham Biosciences, Piscataway, NJ, USA) at the EcoRI and XhoI sites. The resulting plasmids were designated as pGEXERRgLBD.
Experimental procedures
ERRg mutants were generated using PfuTurbo Õ DNA Polymerase (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions using pGEXERRgLBD as a template. The mutations were introduced by PCR mutagenesis in a two-step reaction essentially as reported (14, 18) . Each mutant LBD was amplified and cloned into the vector pGEX-6p-1 at the EcoRI and XhoI sites. All PCR products were verified for their accuracy in the sequences.
ERRcLBD protein expression
Two glutathione S-transferase (GST)-fused receptor proteins-the wild-type and mutant GSTERRgLBD-were expressed in Escherichia coli BL21 as described previously (1) . The receptor protein was purified using an affinity column of glutathionesepharose 4B (GE Healthcare BioSciences Co., Piscataway, NJ, USA). After incubation for 1 h at 4 C, the column was washed three times with PBS containing 0.2% (v/v) Triton X-100 and once with sonication buffer. Fusion protein was eluted with 1 M TrisHCl (pH 8.0) containing 20 mM reduced glutathione, which was removed by gel filtration on a column of Sephadex G-10 (15 Â 100 mm, GE Healthcare) equilibrated with 50 mM TrisHCl (pH 8.0). The purity was confirmed by SDSPAGE using 12.5% polyacrylamide X. Liu et al.
gel. The protein concentrations were determined by the Bradford method (19). C for 2 h with the receptor proteins-GST-fused wild-type ERRgLBD or its mutants-in 100 ml of binding buffer [10 mM HEPES (pH 7.5), 50 mM NaCl, 2 mM MgCl 2 , 1 mM EDTA, 2 mM CHAPS and 2 mg/ml g-globulin]. The assay was performed with or without the addition of unlabelled BPA or 4-OHT (final concentration of 1 Â 10 À5 M) to quantify the specific and nonspecific binding. After incubation with 100 ml of 1% dextran-coated charcoal (DCC) (Sigma) (21) in PBS (pH 7.4) for 10 min at 4 C, free radioligand was removed by the direct vacuum filtration method using a 96-well filtration plate (Millipore, Bedford, MA, USA) for the B/F separation. The specific binding of [ 3 H]BPA or [ 3 H]4-OHT was calculated by subtracting the non-specific binding from the total binding, and the results were examined by Scatchard plot analysis (22) . The assay was carried out at least in triplicate.
Radio-ligand receptor binding assays
Competitive binding. Competitive binding assays were performed in the presence of GST-fused wild-type ERRgLBD or its mutants at the most appropriate concentration of each. Reaction mixtures were incubated with either [ 3 H]BPA or [ 3 H]4-OHT (5 nM in final) at 4 C for 2 h, and free radioligand was removed by the method described above after incubation with 100 ml of 1% DCC in PBS (pH 7.4) for 10 min at 4 C. To estimate the binding affinity, the IC 50 values (the concentrations for the half-maximal inhibition) were calculated from the dose-response curves evaluated by the nonlinear analysis program ALLFIT (23) . Each assay was performed in duplicate and repeated at least three times.
Results
Critical structural elements to detain 4-OHT and BPA to ERRc For the receptor binding assays, the ERRgLBD (residues 222458) was expressed in E. coli as a protein fused with glutathione S-transferase (GST). Mutations were introduced by the PCR mutagenesis method for the original nucleotide triplet codons GAG of Glu275 and CGG of Arg316 (24) . To evaluate the ligandbinding ability of mutant receptors, a saturation binding assay was first performed using GSTERRgLBD and [
3 H]4-OHT. In this assay for the mutant receptors, especially when no specific binding was measurable under the same experimental conditions for the wild-type ERRg receptor, the assay was carried out repeatedly for the specified times using varied concentrations of the receptor GSTERRgLBD or radio-ligand [
3 H]4-OHT. In the previous study using [ 3 H]BPA, it was found that Glu275 and Arg316 are necessary for holding BPA and 4-OHT in ERRg, but with different degrees of involvement in the hydrogen bonding (14) . This result was further evidenced in the present study using [
3 H]4-OHT and a series of mutant receptors, in which site-directed mutations in the LBD of ERRg were carried out for positions 275 and 316. When Glu275 and Arg316 were simultaneously mutated to Ala, the resulting (Ala, Ala)-ERRg mutant receptor exhibited no specific binding of [ 3 H]4-OHT, as reported for [ 3 H]BPA (14) . As the X-ray crystal structure has suggested (12, 15) , the results clearly indicated that Glu275 and Arg316 are crucial for the binding of 4-OHT and BPA, whose phenol-hydroxyl groups are indeed engaged in hydrogen bonding with the side chain carboxyl (Glu) and guanidino groups (Arg). Table I ). The present results clearly indicate that the hydrogen bonds between the phenol-hydroxyl group of 4-OHT or BPA and the Glu275 and Arg316 residues are necessary for capturing these chemicals in the binding pocket of ERRgLBD. However, it is also clear that the hydrogen bond between 4-OHT/BPA and the Arg316 is much more important than that between 4-OHT/BPA and the Glu275.
Receptor binding results were also obtained by a competitive binding assay using [
3 H]4-OHT as a tracer (Table II) . BPA and 4-OHT elicited almost the same results for the wild-type ERRg, with IC 50 values of 13.8 and 10.3 nM, respectively. For (275Ala)-ERRg, the IC 50 values were 365 nM (3.6% of the binding affinity for the wild-type ERRg) and 356 nM (3.9%), respectively. However, for (316Ala)-ERRg with the Arg!Ala mutation, the competitive binding assay could not be carried out because of the extremely small specific binding in the saturation-binding assay. These results clearly indicate that the hydrogen bonding to the Arg316 residue is much more important for capturing BPA and 4-OHT than that to the Glu275 residue. Glu275 and Arg316 as hydrogen-bonding anchors to tether the ligands When Glu275 and Arg316 were each replaced by Leu instead of Ala, the resulting (275Leu)-ERRg and (316Leu)-ERRg mutant receptors were completely inactive, with no specific binding (Table I) . Thus, it was impossible to carry out their competitive binding assays (Table II) . When Glu275 was replaced by glutamine (Gln), the resulting (275Gln)-ERRg mutant receptor exhibited a sufficient specific binding ($70% of the total binding) for (Table I ). The IC 50 values of BPA and 4-OHT were 179 nM (5.1% of the binding affinity for the wild type) and 184 nM (6.2%), respectively (Table II) . These results are rather worse than those obtained for (275Ala)-ERRg. It is therefore clear that Gln does not compensate for Glu, indicating that the carboxyl (COOH) group, but not the carboxyl amide (CONH 2 ) group, is crucial to capturing BPA and 4-OHT.
For (275Asp)-ERRg with the Glu275!Asp substitution, [ 3 H]4-OHT exhibited just barely sufficient specific binding ($30% of the total binding) (data not shown). It was found that (275Asp)-ERRg affords almost the same results obtained for (275Ala)-ERRg and (275Gln)-ERRg (Tables I and II) . In particular, BPA and 4-OHT are significantly weak for binding to this mutant receptor (4-8% of the binding affinity for the wild-type ERRg) (Table II) . All these results indicate that the g-carboxyl group of Glu275 is crucially important to binding BPA and 4-OHT.
The importance of Arg316 was also demonstrated by another mutation, in which the basic Arg residue was replaced by lysine (Lys) with the amino group. (Table II) . Furthermore, the inactivity of (316Leu)-ERRg and the extremely weak activity of (316Ala)-ERRg (Tables I and II) definitely reveal the importance of the basic Arg residue for receptor activation. All these results indicate that Arg316 is a very important structural element for the binding of BPA and 4-OHT to the binding pocket of ERRgLBD by hydrogen bonding.
Collectively, it is now clear that Glu275 and Arg316 are necessary for holding BPA and 4-OHT in ERRg, but with different degrees of involvement in the hydrogen bonding. The results clearly indicate the major importance of phenol-hydroxyl$Arg316 hydrogen bonding and the supportive role of the phenolhydroxyl$Glu275 hydrogen bonding. The difference in their significance might be attributable to the importance and/or necessity of receipt of the phenol-hydroxyl group, even by using an assisting group to facilitate the receptor function. These results are coincident with those evidenced by [ 3 H]BPA, as reported previously (14) .
(Glu275, Arg316)-binding site arranged ideally to arrest the phenol-hydroxyl groups In our previous study (14) , hypothesizing that no amino acids other than 316Arg and 275Glu would play such an intrinsic role in capturing the phenolhydroxyl group, we prepared a (Arg, Glu)-ERRg double mutant receptor, in which Arg and Glu were placed simply in opposite order. Due to the significance of the receipt of the phenol-hydroxyl group, for example, of BPA and 4-OHT, we expected that the Arg and Glu residues would be transferable. In fact, [ 3 H]BPA was found to bind to this (Arg, Glu)-ERRg double mutant receptor (14) . However, its binding potency was almost 10 times weaker than that to the wild-type receptor (Table I ). In the present study, almost the same result was obtained for [ Table I. [ 3 H]4-OHT bound to (Arg, Glu)-ERRg with a dissociation constant of 77.3 nM, showing only one-seventh the strength of the bond to the wild-type receptor (Table I) .
The specific binding of [ 3 H]BPA was $65%. In contrast, [ 3 H]4-OHT exhibited only a very small specific binding (520%) in relation to the total binding. Thus, since [ 3 H]4-OHT could only barely bind to (Arg, Glu)-ERRg, it was impossible to carry out the competitive binding assay (Table II) .
As to the (Arg, Glu)-ERRg receptor, we made further Ala substitutions for 275Arg and 316Glu, respectively. The resulting (Ala, Glu)-ERRg mutant receptor with the 275Arg!Ala substitution was found to completely lack the binding capability for [ 3 H]BPA and [ 3 H]4-OHT (Table I ). In contrast, the Arg-containing (Arg, Ala)-ERRg mutant receptor was still active (Table II) .
The fact that the Arg-containing (Arg, Glu)-ERRg and (Arg, Ala)-ERRg mutant receptors were still active, but (Ala, Glu)-ERRg with no Arg was completely inactive, led us to conclude that phenolhydroxyl$275Arg hydrogen bonding plays a primary role, while the role of phenol-hydroxyl$316Glu hydrogen bonding is only supportive. Furthermore, our finding that (Arg, Glu)-ERRg and (Arg, Ala)-ERRg are almost equipotent (Table I) indicates that the supportive role of the phenol-hydroxyl$316Glu hydrogen bond is actually almost insignificant. This together with the result that these mutant receptors have considerably lower affinity to BPA and 4-OHT is apparently due to the mismatched proximity to the phenol-hydroxyl group of BPA and that of 4-OHT. This assumption was proved recently by the X-ray crystal structure analysis of the BPA/(Arg, Glu)ERRg complex (under submission). Although Glu275 and Arg316 in ERRg are interchangeable for keeping up the interaction with BPA and 4-OHT, ERRg appears to afford simultaneously an ideal space and the capability of arresting the phenolhydroxyl groups by arranging the Glu and Arg residues at positions 275 and 316, respectively. (Fig. 3, Table II ). It should be noted that the competitive binding assay measures the ability of the compound to replace the radiolabelled tracer in the ligand-binding pocket of the receptor. Thus, the results simply imply that, for BPA, to replace The maximal receptor density (B max ) was estimated by Scatchard plot analysis for each mutant receptor in which specific binding was observed (Fig. 4) 
Discrepancy in potency to

Discussion
Structural requirements of ERRc to bind BPA and 4-OHT Among the total 48 human NRs, 26 NRs have Arg at the position corresponding to ERRg's 316 (14) . In contrast to this Arg316, Glu275 is conserved among only five NRs: ERa, ERb, ERRa, ERRb and ERRg.
Since all these Glu275-containing NRs contain Arg316, it is very reasonable to assume that these (Glu275, Arg316)-containing NRs are able to bind to the phenol compounds. We have recently demonstrated that a number of 4-alkylphenols bind to ERRg considerably more strongly (11) , and that their phenol-hydroxyl group is arrested by the Glu275 and Arg316 residues, as shown by the X-ray structural analysis of the phenol/ERRg complexes (unpublished data). Although the natural hormone of ERa and ERb is 17b-estradiol, ERRa, ERRb and ERRg are all orphan receptors whose endogenous ligand is not identified (2528). It is highly likely that if the ERRs have any endogenous ligands, they must be phenol compounds.
When the Glu275!Ala substitution was accomplished, the resulting mutant receptor (275Ala)-ERRg was found to exhibit just about sufficient specific binding ($35% of the total binding) for (Fig. 1) , which has been demonstrated to occupy the same (Glu275, Arg316)-binding site in the ERRg receptor (12, 15, 29, 30) . Thus, their different receptor binding modes are definitely due to structures other than the phenol group.
For the ERRg receptor, 4-OHT acts as an inverse agonist (1, 16) , the binding of which dissociates the a-helix 12 (H12) region from the LBD body (12, 15, 29) . This discussion results in a deactivation of the receptor. 4-OHT puts aside the H12 from an activation conformation to an inactivation conformation, as evidenced by the X-ray crystallography of the 4-OHTERRg complex (15) . This process appears to be a highly energy-consuming option. In contrast, H12 of non-liganded ERRgLBD is folded into the activation conformation (12, 29) , and BPA is able to bind to this conformation without causing any structural changes in the receptor, as demonstrated by the X-ray crystallography of the BPAERRg complex (12) . Thus, there is indeed a distinct difference in binding modes between 4-OHT and BPA for ERRg. BPA suppressed the inverse agonist activity of 4-OHT, being a specific inhibitor against the inverse agonist 4-OHT. It should be noted that BPA's ability to antagonize 4-OHT is approximately one-order lower than its binding potency to ERRg, as reported previously by Okada et al. (11) . This discrepancy is probably due to the BPA's difficulty in displacing 4-OHT (see above in the Results section), originating from the distinction in binding modes between BPA and 4-OHT for ERRg.
